NCT04546009
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 62 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Study completion pushed from Jul 31, 2027 to Jul 28, 2028
- Study sites: 255 to 256
- Secondary endpoints: details revised at 2 of 13 entries
- Minor Study completion moved earlier from Mar 25, 2028 to Jul 31, 2027
- Study sites: 256 to 255
- Minor Study sites revised (256)v60
- Minor Study sites: 255 to 256
- Primary completion date changed from estimate of Feb 1, 2026 to Jan 30, 2026
- Minor Study sites: 257 to 255
- Primary completion date: Dec 15, 2025 to Feb 1, 2026
Show 45 earlier versionsHide 45 earlier versions
- Minor Study sites: 261 to 257v57
- Minor Study sites: 263 to 261v56
- Minor Primary completion date: Oct 10, 2025 to Dec 15, 2025
- Study sites revised (263)
- Notable Primary completion date: Mar 31, 2025 to Oct 10, 2025
- Study sites: 278 to 263
- Minor Study sites: 279 to 278v53
- Minor Study sites: 281 to 279
- Study completion date: Mar 18, 2027 to Mar 25, 2028
- Minor Site details revised at 1 of 281 sitesv51
- Minor Study sites: 283 to 281v50
- Minor Study sites: 291 to 283v49
- Minor Study sites: 300 to 291v48
- Minor Study sites: 332 to 300v47
- Notable Primary completion date: Apr 26, 2024 to Mar 31, 2025
- Study sites: 346 to 332
Notable Eligibility criteria shortened, about 14 wordsv45 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 978 to confirmed 992
- Study sites: 390 to 346
- Secondary endpoints revised (13)
- Minor Study sites revised (390)v44
- Minor Study sites: 389 to 390v43
- Minor Study sites: 387 to 389v42
- Notable Eligibility criteria expanded, about 2 words
- Study sites: 386 to 387
- Minor Study sites: 384 to 386v40
- Minor Study sites: 377 to 384v39
- Minor Study sites: 375 to 377v38
- Minor Study sites: 373 to 375v37
- Minor Study sites: 371 to 373v36
- Minor Study sites: 365 to 371v35
- Minor Study sites: 362 to 365v34
- Minor Study sites: 355 to 362v33
- Minor Study sites: 354 to 355v32
- Minor Study sites: 347 to 354v31
- Minor Study sites: 339 to 347v30
- Minor Study sites: 333 to 339v29
- Minor Study sites: 324 to 333v28
- Minor Study sites: 316 to 324v27
- Minor Study sites: 313 to 316v26
- Minor Study sites: 308 to 313v25
- Minor Study sites: 305 to 308v24
- Minor Study sites: 298 to 305v23
- Minor Study sites: 291 to 298v22
- Minor Study sites: 287 to 291v21
- Minor Study sites: 279 to 287v20
- Minor Study sites: 268 to 279v19
- Minor Study sites: 249 to 268v18
- Minor Study sites: 228 to 249v17
- Minor Study sites: 221 to 228v16
- Minor Study sites: 212 to 221v15
- Minor Study sites: 203 to 212v14
- Minor Study sites: 182 to 203v13
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1
Timeframe: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)
Secondary (13)
Overall Survival
Objective Response Rate, as Determined by the Investigator According to RECIST v1.1
Duration of Response, as Determined by the Investigator According to RECIST v1.1
Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1
Time to Confirmed Deterioration in Pain Level, Defined as the Time to First Documented ≥2-Point Increase from Baseline in the 'Worst Pain' Item from the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire
Show 8 moreShow less
Time to Confirmed Deterioration in Pain Presence and Interference, Defined as the Time to First Documented ≥10-Point Increase from Baseline in the EORTC QLQ-C30 Linearly Transformed Pain Scale Score
Time to Confirmed Deterioration in Physical Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Physical Functioning Scale Score
Time to Confirmed Deterioration in Role Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Role Functioning Scale Score
Time to Confirmed Deterioration in Global Health Status and Quality of Life (GHS/QoL), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed GHS/QoL Scale Score
Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)
Number of Participants with Vital Sign Abnormalities Over the Course of the Study
Plasma Concentration of Giredestrant at Specified Timepoints
Plasma Concentration of Palbociclib at Specified Timepoints
Arms and interventions
Giredestrant + Letrozole-matched Placebo + PalbociclibExperimental
Letrozole + Giredestrant-matched Placebo + PalbociclibActive comparator
Drugs: Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist
Sites
256 sites in 30 countries
United States 38, Japan 22, Germany 19, China 17, South Korea 13, Spain 13, Canada 11, Italy 11, United Kingdom 10, France 9, Turkey (Türkiye) 9, Brazil 8, Russia 8, Argentina 7, Mexico 7, Australia 6, Taiwan 6, Thailand 5, Ukraine 5, Greece 4, Peru 4, Portugal 4, Austria 3, Denmark 3, Hong Kong 3, Israel 3, Poland 3, Belgium 2, Hungary 2, New Zealand 1